Loss of Microbiota-Mediated Colonization Resistance to Clostridium difficile Infection With Oral Vancomycin Compared With Metronidazole.

TitleLoss of Microbiota-Mediated Colonization Resistance to Clostridium difficile Infection With Oral Vancomycin Compared With Metronidazole.
Publication TypeJournal Article
Year of Publication2015
AuthorsLewis BB, Buffie CG, Carter RA, Leiner I, Toussaint NC, Miller LC, Gobourne A, Ling L, Pamer EG
JournalJ Infect Dis
Volume212
Issue10
Pagination1656-65
Date Published2015 Nov 15
ISSN1537-6613
KeywordsAnimals, Anti-Infective Agents, Bacterial Infections, Clostridium difficile, Disease Models, Animal, Disease Resistance, Escherichia coli, Female, Klebsiella pneumoniae, Metronidazole, Mice, Inbred C57BL, Vancomycin, Vancomycin-Resistant Enterococci
Abstract

Antibiotic administration disrupts the intestinal microbiota, increasing susceptibility to pathogens such as Clostridium difficile. Metronidazole or oral vancomycin can cure C. difficile infection, and administration of these agents to prevent C. difficile infection in high-risk patients, although not sanctioned by Infectious Disease Society of America guidelines, has been considered. The relative impacts of metronidazole and vancomycin on the intestinal microbiota and colonization resistance are unknown. We investigated the effect of brief treatment with metronidazole and/or oral vancomycin on susceptibility to C. difficile, vancomycin-resistant Enterococcus, carbapenem-resistant Klebsiella pneumoniae, and Escherichia coli infection in mice. Although metronidazole resulted in transient loss of colonization resistance, oral vancomycin markedly disrupted the microbiota, leading to prolonged loss of colonization resistance to C. difficile infection and dense colonization by vancomycin-resistant Enterococcus, K. pneumoniae, and E. coli. Our results demonstrate that vancomycin, and to a lesser extent metronidazole, are associated with marked intestinal microbiota destruction and greater risk of colonization by nosocomial pathogens.

DOI10.1093/infdis/jiv256
Alternate JournalJ. Infect. Dis.
PubMed ID25920320
PubMed Central IDPMC4621244
Grant ListT32GM07739 / GM / NIGMS NIH HHS / United States
P30 CA008748 / CA / NCI NIH HHS / United States
AI95706 / AI / NIAID NIH HHS / United States
R01 AI095706 / AI / NIAID NIH HHS / United States
R01 AI42135 / AI / NIAID NIH HHS / United States
R01 AI042135 / AI / NIAID NIH HHS / United States
T32 GM007739 / GM / NIGMS NIH HHS / United States

Person Type: